Episodes / Mushrooms for the Mind & Immune System | Paul Stamets /
Full transcript
Mushrooms for the Mind & Immune System | Paul Stamets · 2:28:55 · 2388 segments · transcribed with distil-large-v3 on Nov 17, 2026. Timestamps open the source at that second.
-
Because I think it's illustrative.
-
In June of 2001, I published an article in a journal called Erbilgram, the American Botanical Council.
-
And what happened was in the 1970s, Dr. Frank Perano from the University of Washington Medical School, I met him at a conference.
-
And he said, Paul, I'm a virologist.
-
I found some antiviral properties and mushrooms.
-
Can you get me the gypsy mushroom?
-
It was called Verzaitis caparata, cortinarius caparatas now.
-
It's a microasal mushroom.
-
It grows in the forest.
-
And most microorganosal mushrooms, we can't grow.
-
So it has to be collected.
-
It can't be grown.
-
So I was a young, young mycologist, and I met this great medical doctor.
-
And so I, back in the day, when the Federal Express first started, I shipped him like 20 pounds of gypsy mushrooms.
-
He ended up isolating a novel glycoprotein called RC-183, highly active against herpes viruses.
-
So I thought to myself, well, great, Frank, you found this antiviral properties of the mushrooms.
-
I'm going to survey the scientific literature.
-
So I did a deep dive.
-
and I published a one-page article with all the scientific research I could find on the antivial properties of Russians.
-
I published that in June 2001, 9-11 occurred.
-
A physician involved the BioProject Bio-Defense, BioShield, saw my article, reached out to me and saying,
-
listen, we're really concerned about weaponizable viruses, smallpox in particular, flu, et cetera.
-
There's a program, and we're doing a wide nut.
-
we need to potentiate host defense against potential pathogens.
-
So I had a laboratory.
-
I have a small business.
-
You know, it's fungi, perfect eye.
-
We have a host defense product line.
-
I created the business to do research.
-
So I had amassed hundreds of cultures and, you know, hundreds of species.
-
So they gave me carte blanche and I could just shotgun.
-
So I sent them, and they did 2,200, I think, and 65 assets.
-
for free, and I shotguned massive amounts of material.
-
I had an opportunity of a lifetime, you know?
-
So I gave mushroom fruit body extracts,
-
the mycelium that made those mushrooms, those extracts,
-
and I got the research results back,
-
and they were phenomenal,
-
especially against orthopoxes and against flu viruses.
-
So when I got the research results,
-
I got a lot of attention.
-
I got more resources.
-
I got virologists going,
-
what is going on.
-
And you could actually listen to National Public Radio, myself, the deputy director of the FDA,
-
and the head of the Bowshield program.
-
We are in the top 10 of more than 2 million samples surveyed.
-
We're the only natural product, but the top 10 of super selectivity against weaponizable viruses.
-
So that was great.
-
And it localized into this old growth mushroom called a garricon.
-
Now, I described most restaurants rot in a few days.
-
That's true with oyster and shi-taki and mitaki mushrooms.
-
But Agarikon is one of the longest living mushrooms in the world.
-
It grows for more than 100 years.
-
It grows in the old growth forest.
-
It's now on the red list of extinction in Europe.
-
You can't pick it legally.
-
We still have it in our old growth for us in northern California, Washington, Oregon, British Columbia,
-
and also Montana and a little bit northern Arizona.
-
So in the 1980s, I started, had focused on Agaricon because it was such a
-
mesmerizing mushroom is the only species in its genus, and it's the only genus in its family.
-
So it's only species in its family, the two other species just recently entered into the
-
landscape, but racy mushrooms have 300 species. So here's this thing that we did full genetic
-
analysis. We just published in G3, genes, genomes, and genetics, the full genome sequencing of
-
Agaricon, first one in history. But this is a great story because I started digging into
-
Agaricon, and Diascorides first described it in the first material in America in 65 AD as
-
Elexerium ad longum vitum, the elixir of long life. What a beautiful name. Yeah. So you have this
-
elixir of long life, longevity mushroom. It's been used for thousands of years, grows in the old
-
growth forest. And so I did a deep dive on this. And this is what our research comes to today,
-
because we did have a big pandemic.
-
And in 2020, I was approached by a group of people
-
who had seen my research that we had published.
-
What can you do with COVID?
-
And there was also an urgency.
-
And so we proposed, and we bundled a garacan and turkey tail.
-
We have a host defense product line.
-
It's the very same material that was going into our nutraceutical product line.
-
We just bundled them together, Agarokon and Turkey Tail.
-
We published three papers on Turkey Tail.
-
Now, the FDA, the first thing they said is we don't want to over-stimulate the immune system.
-
Most people die from a cytokine storm.
-
From COVID, Ebola, flu viruses, people die from the cytokine storm, an overexpression of the immune system.
-
Fortunately, we had a breast cancer clinical study in, I think, 2012.
-
In 2019, we found that when you grow the mycelium on rice,
-
separate from the mycelium, separate from the fruit body, it ferments the rice into a microfermended
-
unique product.
-
We published in the Journal of Inflammation Research that it stimulates interleukin 10 and interleukin 1RA.
-
As you know, anti-inflammatory cytokines.
-
So we could upregulated immunity, but we could suppress the overexpression of the immune system
-
by having these anti-inflammatory cytokines.
-
So we passed the test with the FDA.
-
They wanted that we can't over-stimulate the immune system, people will die quicker, and how do you know this is safe?
-
Fortunately, we had all the safety data.
-
I had the Bioshield data, which I also had published on.
-
So we bundle these two things together.
-
It's been an extraordinary story.
-
It's been privately funded through the Krups Institute of Integrative Medicine at the University of California, San Diego, and UCLA Medical School.
-
So we have 140 patients in two studies, and we just published in BMC Immuneration.
-
the results for vaccine enhancement.
-
We published that one first because we're going to have a natural product trying to mitigate,
-
you know, COVID.
-
You can imagine the blowback we would get.
-
Well, half the country would just want to take that.
-
Perhaps the more traditionalists would, in my mind, would think, okay, they're trying to
-
create a replacement for vaccines and would probably buckle.
-
That we have to hit this wall of antipathy.
-
that conventional medical doctors and scientists have against natural products,
-
even though the majority of medicines have their origins in natural products.
-
But you have this thing of fractionation to one molecule versus the synergism of the complexity.
-
We kept the complexity in place.
-
And so our double-blind placebo-controlled clinical studies showed enhancement of MRNA vaccines
-
from Pfizer and Moderna.
-
and the big result that we got was of the 10 symptoms that are associated with adverse reactions
-
to vaccines, and I just got a vaccine against COVID, like, eight days ago, and I take a Garikon
-
on Turkey Tail, and I had no adverse effects. I couldn't even tell I got a vaccine.
-
It's because of the blunted inflammation. What we showed in a study was a statistically
-
significant reduction of adverse reactions to the vaccines, which is remarkable compared to the
-
placebo, which was the rice. So it's the mycelium on rice. It's, it, this is immunologically unique
-
product. It's very different and better than the mycelium, very different and better than the
-
mushroom fruit bodies. So the real surprise on this, Gordon Sachs, Andrew Schuboff, Christine,
-
Hector, and other individuals who are part of this team, there's like 10 or 12 co-authors on these
-
papers, is to their credit, they decided, since they banked the blood of these 90 participants,
-
they decided six months later,
-
let's have the patients come back
-
and draw their blood.
-
This was not my idea.
-
This is the genius of our team
-
who came up with this idea.
-
They withdrew the blood.
-
And it turns out statistically significant.
-
Those people who took a garacom on turkey tail
-
and had the vaccine had triple the antibody reservoirs
-
against COVID, then those individuals
-
who just got the vaccine.
-
Not only would we reduce the adverse effects
-
of vaccination, but we extended antibody
-
the immunity, and they only took it for four days.
-
Think about the extension of innate immunity.
-
And so this really got our minds thinking, how is this working?
-
And our hypothesis, again, we have the results.
-
Mechanisms of action, we can debate that all day long.
-
But we think what it's doing, it elevates immunity to a higher state of readiness.
-
So your endogenous immune system can customize, antibodies specific to the pathages,
-
is trying to protect the system, the host.
-
And the advantage of vaccines and their vulnerability is there are hyper-selectivity.
-
So you get vaccine evasion from the viruses because they're really good at target-specific,
-
but then the viruses mutate.
-
And then you have immunologically compromised people who are mutating all sorts of, you know,
-
vaccine-resistant, you know, viral strains.
-
This is why we have vaccines that are different every season, right?